Mantzavinos and Alexiou has recently reported the important biomarkers for AD. Concurrently, biomarkers that indicate a high likelihood of Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI) may be more precise if both Amyloid-β (Aβ) and neuronal injury biomarkers test positive. Solely assessing Aβ protein can only provide us with an intermediate probability of developing AD due to MCI. If there is only one biomarker of neurological damage present and Aβ cannot be measured, then these patients will be presumed to have a lower probability of developing AD. Another study on age and its impact on AD progression mentioned the density of pathological lesions in relation to the age of the subject . Furthermore, several studies indicate that age is a critical factor in the development of AD In addition to this, AD can be categorized into early onset familial AD, where the disease typically develops before the age of 60 years. In such cases, the onset of AD signifies a hereditary disease that is inherited in an autosomal dominant manner . Alzheimer's disease is mainly characterized by the Aβ protein pathology found in the amyloid precursor protein gene on the long arm of chromosome 21 . The accumulation of Aβ deposits leads to the creation of plaques, which are amyloid fibrils that gather in the cell's outer space and form globular shapes. In some cases, Aβ can also be deposited in the media and adventitia of small and mid-sized arteries, a condition referred to as Cerebral Amyloid Angiopathy . Moreover, both cerebrospinal fluid (CSF) and plasma can be used to detect and quantify Aβ through positron emission tomography scanning, which detects fibrillar Aβ.